Laccure Pessary developed for treatment and prevention of bacterial vaginosis now ready for commercialisation

Sep 1 2015

The Swedish company Laccure AB has developed a breakthrough women's health product that is effective, safe and user-friendly. Laccure's owners are now aiming to divest the company to a buyer with appropriate resources to launch the product.

The manufacturing process for the new product, Laccure® Pessary, has now been scaled up and the product is ready for market introduction. Laccure has therefore initiated a search for an established company interested in acquiring Laccure and launching the product. Evli Corporate Finance is retained for the exit process.

"We are proud to announce that the final development stage, the up-scaling of the manufacturing process for Laccure® Pessary, our new antibiotic-free, non-prescription product for the treatment and prevention of bacterial vaginosis, is now completed. The product is thus ready for launch. Our objective from the start of the project has been to sell Laccure to a company that will take the product to market," says Dr Jeanette Robertsson, CEO of Laccure AB.

Bacterial Vaginosis

Bacterial vaginosis (BV) is the most common vaginal infection in women of childbearing age, affecting more than 300 million women worldwide each year. Today, there is a lack of effective and safe products that are also user-friendly and can be dosed with low frequency. Women are often embarrassed at having BV and their quality of life is negatively affected. BV is an imbalance of naturally occurring vaginal bacterial flora, resulting in a lack of vaginal acidity, discharge with a pronounced foul odour and inhibition of normal lactobacilli growth. Frequent recurrences are common.

Laccure® Pessary

The new, patented product is based on a proprietary substance that releases lactic acid over several days to decrease the elevated vaginal pH. The development work has focused on creating a user-friendly, non-smear product that is easy to insert and highly effective. This has been demonstrated in clinical studies, in which 80% of the women were free of their BV after a single dose. Laccure® Pessary need only be administered once a month to prevent recurrence. Laccure® Pessary is CE-marked as a Class IIa medical device and is now ready for market introduction in the EU/EES countries.

SOURCE Laccure AB